ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
03/12/2026
Back to search
Official data from USPTO
ASCENDIS PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
72
Latest update
03/13/2026
Trademark type
Combined
Nice classes
5, 42, 45
Filing date
10/11/2017
Registration date
02/01/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/01/2022
Last transaction
03/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
DK
Examiner
SHOOR, AMIT KUMAR
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the turquoise word "ASCENDIS" under which is the grey word "PHARMA" next to a polygon broken by a white curved band in which the top is turquoise and the bottom is blue.
Holders and representatives
Holders
Ascendis Pharma A/S
Ascendis Pharma A/S
Representatives
Eric T. Fingerhut Dykema Gossett PLLC
Technical classification
Nice Classes
Class 5Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparations for the treatment of physical and mental illnesspharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparationsvaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illnesspharmaceutical preparations for the prevention and treatment of disorders of the endocrine systemgrowth hormone deficiencieshypoparathyroidismachondroplasiadiabetesfibroblast growth factor receptor(FGFR)-related skeletal disordersoncological disordersophthalmologic disordersinfectious diseasesenzyme replacement therapyanti-inflammatory diseasespainrespiratory system disordersautoimmune disordersvaccinesnon-alcoholic steatohepatitisbrain diseasesbone diseasesCNS diseasesmyopathiesobesitywounds healingthe hormonal system disordersgrowth hormone deficienciesdiabetes and angiogenesisthe ophthalmological system disordersangiogenesisthe angiogenic system disordersthe central nervous system disorderscentral nervous system infectionsbrain diseasescentral nervous system movement disordersocular motility disordersspinal cord diseasesthe immune system disordersimmunologic diseasesautoimmune diseases and immunologic deficiency syndromesthe cardio-vascular system diseasesthe metabolic system disordersdiabeteshypoglycaemiagoutosteoarthritismuscular dystrophyanemiathe respiratory systemthe musculo-skeletal system disordersgrowth hormone deficienciesconnective tissue diseasesbone diseasesspinal diseasesback painfracturessprainscartilage injuriesthe genitourinary system disordersurological diseasesinfertilitysexually transmitted diseasesinflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disordersanti-inflammatories; pharmaceutical preparations for use in dermatologydermatitiseczemapsoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposessanitizing wipesdisinfectants for medical instrumentsadhesive tapes for medical purposesdietetic foodsdietetic sugar substitutes adapted for medical useall-purpose disinfectants for sanitary purposes; fungicidesherbicides
Class 42
Scientific research within the medicalpharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific researchconducting of tests regarding medical applicationsconducting clinical trials for otherspackaging designdesigning and development of medical equipmentdesigning pharmaceutical and medical preparationspreparation of pharmaceutical formulationspharmaceutical products developmentdesign and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology
Class 45
Licensing of industrial property; legal services
Publications
History of USPTO decisions and trademark events.
72 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/10/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/01/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/13/2022
FIMP
FINAL DISPOSITION PROCESSED
07/13/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
02/01/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/24/2021
GPNX
NOTIFICATION PROCESSED BY IB
11/23/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/16/2021
PUBO
PUBLISHED FOR OPPOSITION
11/16/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/28/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/27/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/27/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/27/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/13/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/12/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/12/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/09/2021
GNFR
FINAL REFUSAL E-MAILED
07/09/2021
CNFR
FINAL REFUSAL WRITTEN
07/09/2021
DOCK
ASSIGNED TO EXAMINER
06/10/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/16/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/15/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/15/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/15/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/15/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/15/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/15/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/15/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/15/2021
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
03/15/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
03/15/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2020
GNRT
NON-FINAL ACTION E-MAILED
09/14/2020
CNRT
NON-FINAL ACTION WRITTEN
09/14/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
06/18/2020
ALIE
ASSIGNED TO LIE
06/03/2020
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
11/21/2019
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/05/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/19/2019
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/19/2019
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
05/09/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/19/2018
GNSL
LETTER OF SUSPENSION E-MAILED
10/19/2018
CNSL
SUSPENSION LETTER WRITTEN
10/19/2018
DMCC
DATA MODIFICATION COMPLETED
10/01/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/28/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/27/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/27/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2018
GNRT
NON-FINAL ACTION E-MAILED
09/14/2018
CNRT
NON-FINAL ACTION WRITTEN
09/14/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/17/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/17/2018
ALIE
ASSIGNED TO LIE
08/16/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/26/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/24/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/24/2018
RFNT
REFUSAL PROCESSED BY IB
03/02/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/09/2018
RFRR
REFUSAL PROCESSED BY MPU
02/09/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/07/2018
CNRT
NON-FINAL ACTION WRITTEN
02/06/2018
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
02/02/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/30/2018
CNRT
NON-FINAL ACTION WRITTEN
01/29/2018
MAFR
APPLICATION FILING RECEIPT MAILED
01/23/2018
DOCK
ASSIGNED TO EXAMINER
01/19/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/19/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/18/2018
Continuous trademark protection
Get notified about every new filing that threatens ASCENDIS PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.